Corticosteroid Treatment in the Acute Phase of Caustic Ingestion Management
NCT03760354 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2018-11-30
Summary
The management of patients who have ingested a caustic product has changed since 2007. Whereas previously the lesion assessment and surgical indication were based on endoscopic data, the therapeutic algorithm is currently based solely on the results of a CT scan with contrast injection, performed 6 hours after ingestion. This examination makes it possible to reliably assess the viability of the esophageal and gastric walls and thus to indicate digestive resection. The therapeutic consequences of this new treatment are important because, by expanding the indications for conservative treatment after severe ingestion, it brings a significant gain in terms of survival, morbidity and functional outcome. In the absence of emergency digestive resection, however, the functional prognosis is often overshadowed by the formation of esophageal stenosis in the months following ingestion. Patients then require endoscopic dilation treatment. In the event of failure or impossibility of dilation, which defines refractory stenosis, esophageal reconstruction is necessary. In case of sequential pharyngeal stenosis following ingestion, esophageal and pharyngeal reconstruction is indicated as a first-line treatment, since these stenosis do not respond to endoscopic dilations. The expansion of the indications for conservative treatment after severe ingestion using CT scans has led to an increase in the incidence of after-effect stenosis.
We aim to develop a therapeutic approach that will prevent the development of refractory and pharyngeal esophageal stenosis. Indeed, there is currently no strategy that has proven effective in this regard in adults. The value of corticosteroid therapy for the prevention of caustic stenosis has only been evaluated in children and remains controversial.
The main objective is to evaluate the effect of early systemic corticosteroid therapy on the risk of refractory esophageal or pharyngeal stenosis within one year of ingestion of a caustic substance in a population of patients at high risk of stenosis, defined according to tomodensitometric criteria (grade IIb: severe lesions, absence of transparietal necrosis), and for whom there is no indication of urgent digestive resection.
Conditions
- Caustic Esophageal Injury
- Esophageal Stenosis
- Pharyngeal Stenosis
Interventions
- DRUG
-
Methylprednisolone
Dose: 500mg/day for the first two days then 2mg/kg per day for three days. Dilution in 0.9% NaCl, 100 ml as a single slow intravenous administration over 60 minutes Total processing time of 5 days
- OTHER
-
Placebo
NaCl 0.9%, 100ml per day as a single slow intravenous administration over 60 minutes for a total treatment duration of 5 days
Sponsors & Collaborators
-
Assistance Publique - Hôpitaux de Paris
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-02-15
- Primary Completion
- 2020-02-15
- Completion
- 2023-02-15
More Related Trials
-
The Treatment of Acute Gastrointestinal Injury Via Ultrasound-guided Erector Spinae Plane Block
NCT04934904 ·Status: COMPLETED ·Phase: NA
-
Steroid Versus Mitomycin-C Use in Pediatric Benign Recurrent Esophageal Stricture
NCT06626802 ·Status: COMPLETED ·Phase: NA
-
Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction
NCT02275338 ·Status: COMPLETED ·Phase: PHASE2
-
Pharyngeal Electrical Stimulation for the Treatment of Post-extubation Dysphagia in Acute Stroke
NCT02470078 ·Status: COMPLETED ·Phase: NA
-
Esophageal Food Impaction
NCT03305848 ·Status: COMPLETED ·Phase: PHASE4
-
Prevention of Post-Extubation Laryngeal Edema With Intravenous Corticosteroids
NCT00199576 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants With Symptomatic Diabetic or Idiopathic Gastroparesis
NCT04303195 ·Status: COMPLETED ·Phase: PHASE2
-
Oral Viscous Budesonide in Anastomotic Stricture After Esophageal Atresia Repair (OVB in EA)
NCT03999008 ·Status: UNKNOWN ·Phase: NA
-
Evaluation of Topical Mitomycin C as Adjuvant Drug to Esophageal Dilation in Children
NCT00551824 ·Status: UNKNOWN ·Phase: NA
-
Safety and Efficacy of IV Infusion of Investigational Agent (TZP-101) in Patients With Severe Diabetic Gastroparesis
NCT00612014 ·Status: COMPLETED ·Phase: PHASE2
-
Neuromuscular Electrical Stimulation (NMES) for Dysphagia in Neonates
NCT02007759 ·Status: TERMINATED ·Phase: NA
-
Efficacy, Safety, and Pharmacokinetics (PK) Study of Ulimorelin in Patients With Enteral Feeding Intolerance (EFI): The PROMOTE Trial
NCT02784392 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome
NCT00081458 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458)
NCT00172185 ·Status: COMPLETED ·Phase: PHASE3
-
Short Bowel Syndrome and Teduglutide Versus Placebo
NCT02099084 ·Status: COMPLETED ·Phase: PHASE4
-
Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis
NCT00432835 ·Status: COMPLETED ·Phase: PHASE3
-
Diabetic Gastroparesis Efficacy/Safety Study of TZP-102
NCT01664637 ·Status: TERMINATED ·Phase: PHASE2
-
Direct Peritoneal Resuscitation in Gastroschisis
NCT03205553 ·Status: TERMINATED ·Phase: PHASE1
-
Steroid Treatment After Resuscitated Out-of-Hospital Cardiac Arrest
NCT04624776 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Efficacy and Pharmacokinetic Study of Teduglutide in Infants 4 to 12 Months of Age With Short Bowel Syndrome
NCT03571516 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy Of Oral Dexamethasone Versus Parenteral Dexamethasone In The Management Of Mild To Moderate Croup
NCT06959407 ·Status: COMPLETED ·Phase: NA
-
Evaluation of Some Prognostic Factors in Acute Aluminum Phosphide Intoxicated Cases
NCT05215444 ·Status: COMPLETED
-
A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients With Short Bowel Syndrome
NCT05535361 ·Status: RECRUITING ·Phase: NA
-
Gastric Insufflation Volume Using I-gel Versus Ambu AuraGain in Pediatric Patients Undergoing Elective Orthopedic Operations Under General Anesthesia
NCT06853756 ·Status: RECRUITING ·Phase: NA
-
Feasibility of Aerodigestive Stimulation Therapy Trial
NCT06118697 ·Status: RECRUITING ·Phase: NA